LAS VEGAS, Nevada — Low-dose tricyclic antidepressant therapy is effective in treating moderately severe functional symptoms in patients with inflammatory bowel disease (IBD) who are not experiencing ...

Whether it’s safe to stop anti-TNF treatment in patients with inflammatory bowel disease (IBD) in remission remains unclear. In the Spanish EXIT study, anti-TNF withdrawal in selected patients with ...

Fatigue in IBD 1 year after diagnosis does not appear to be less prevalent even when applying stricter definitions of disease remission. Stricter definitions of remission may not suggest a lower ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis factor (TNF) blockers, new FDA approvals, problems with placebos, and ...

Please provide your email address to receive an email when new articles are posted on . At 1 year, 40% of children with UC and 23% with CD were in sustained steroid-free remission with vedolizumab.

Maintenance treatment with vedolizumab (Entyvio) appeared to be safe and effective in children with inflammatory bowel disease (IBD), with greater effectiveness in those with ulcerative colitis, ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

Mirikizumab is a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis. Pharmaceutical company Eli Lilly recently released findings of two studies ...

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation. It is commonly treated with anti-inflammatory drugs, such as corticosteroids and biologics. Share on Pinterest ...